Back to top
more

Aveanna Healthcare (AVAH)

(Delayed Data from NSDQ)

$3.78 USD

3.78
354,970

-0.04 (-1.05%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $3.78 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

iRhythm's Zio ECG System Gets Approval in Japan, Stock Falls

by Zacks Equity Research

IRTC's Zio ECG monitoring system gets approval in Japan, marking a significant step in revolutionizing arrhythmia diagnostics with AI-powered technology.

Zacks Equity Research

PacBio Stock Drops After Singapore Collaboration for HiFi Sequencing

by Zacks Equity Research

PACB's HiFi sequencing powers the HiFi Consortium's global effort to enhance the diagnosis and treatment of subfertility and recurrent pregnancy loss.

Zacks Equity Research

PacBio's Stock Up on Munster Deal for Male Infertility Research

by Zacks Equity Research

PACB collaborates with the University Hospital of Munster, using Revio HiFi sequencing to advance research on male infertility and rare diseases in Germany and globally.

Zacks Equity Research

Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device

by Zacks Equity Research

FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.

Zacks Equity Research

Why Fast-paced Mover Aveanna (AVAH) Is a Great Choice for Value Investors

by Zacks Equity Research

Aveanna (AVAH) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Are Medical Stocks Lagging Basilea Pharmaceutica (BPMUF) This Year?

by Zacks Equity Research

Here is how Basilea Pharmaceutica AG (BPMUF) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Zacks Equity Research

Should Value Investors Buy Aveanna Healthcare (AVAH) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Indrajit Bandyopadhyay headshot

Aveanna Stock Rallies 110% in 3 Months: Is It Still Worth Buying?

by Indrajit Bandyopadhyay

AVAH stock has the potential to continue its uptrend on the back of a better payer rate environment and its focus on high-paying customers.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Aveanna Healthcare (AVAH) is a Great Choice

by Zacks Equity Research

Does Aveanna Healthcare (AVAH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Despite Fast-paced Momentum, Aveanna (AVAH) Is Still a Bargain Stock

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Aveanna (AVAH) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Is Basilea Pharmaceutica (BPMUF) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Basilea Pharmaceutica AG (BPMUF) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Zacks Equity Research

Are Investors Undervaluing Aveanna Healthcare (AVAH) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Aveanna (AVAH) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Aveanna Healthcare (AVAH) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Aveanna (AVAH) delivered earnings and revenue surprises of 150% and 2.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Curious about Aveanna (AVAH) Q2 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Aveanna (AVAH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

Zacks Equity Research

The Pennant Group, Inc. (PNTG) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

The Pennant Group (PNTG) delivered earnings and revenue surprises of 14.29% and 7.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?

by Zacks Equity Research

Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Zacks Equity Research

Best Momentum Stocks to Buy for July 12th

by Zacks Equity Research

IKNA, AVAH, and VEL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2024.

Zacks Equity Research

Is Aveanna Healthcare (AVAH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aveanna Healthcare (AVAH) and Alcon (ALC) have performed compared to their sector so far this year.

Zacks Equity Research

Compared to Estimates, Aveanna (AVAH) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Aveanna Healthcare (AVAH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aveanna (AVAH) delivered earnings and revenue surprises of 40% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Countdown to Aveanna (AVAH) Q1 Earnings: Wall Street Forecasts for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Aveanna (AVAH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

Zacks Equity Research

Addus HomeCare (ADUS) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 10% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aveanna (AVAH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Aveanna (AVAH) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Aveanna Healthcare (AVAH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aveanna (AVAH) delivered earnings and revenue surprises of 50% and 3.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?